| Trial ID: | L3500 |
| Source ID: | NCT03202095
|
| Associated Drug: |
Creatine Monohydrate
|
| Title: |
Creatine for Treatment of Depression Associated With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
WITHDRAWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Major Depressive Disorder
|
| Interventions: |
DRUG: Creatine Monohydrate
|
| Outcome Measures: |
Primary: Change from Baseline in Hamilton Depression Rating Scale, The purpose of this study is to determine whether 12 weeks of dietary creatine augmentation with oral 5 g creatine daily reduces hypoxia-related depressive symptoms measured by the 17-item Hamilton Depression Rating Scale (HAM-D) in women with SSRI or SNRI resistant depression., 12 weeks |
|
| Sponsor/Collaborators: |
Sponsor: University of Utah
|
| Gender: |
FEMALE
|
| Age: |
ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
0
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2017-08-01
|
| Completion Date: |
2024-06-10
|
| Results First Posted: |
|
| Last Update Posted: |
2024-06-11
|
| Locations: |
University of Utah, Salt Lake City, Utah, 84108, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT03202095
|
